Hortobagyi GN - Search Results

1

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Esteva FJ, et al. Among authors: hortobagyi gn. J Clin Oncol. 2002 Apr 1;20(7):1800-8. doi: 10.1200/JCO.2002.07.058. J Clin Oncol. 2002. PMID: 11919237 Clinical Trial.

2

Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap HY, Gutterman JU, Blumenschein GR. Swenerton KD, et al. Among authors: hortobagyi gn. Cancer Res. 1979 May;39(5):1552-62. Cancer Res. 1979. PMID: 427797

3

Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).

Buzdar AU, Blumenschein GR, Smith TL, Tashima CK, Hortobagyi GN, Yap HY, Gutterman JU, Hersh EM, Gehan EA. Buzdar AU, et al. Among authors: hortobagyi gn. J Surg Oncol. 1979;12(1):27-40. doi: 10.1002/jso.2930120105. J Surg Oncol. 1979. PMID: 480951

4

Complete remissions in metastatic breast cancer treated with combination drug therapy.

Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ. Legha SS, et al. Among authors: hortobagyi gn. Ann Intern Med. 1979 Dec;91(6):847-52. doi: 10.7326/0003-4819-91-6-847. Ann Intern Med. 1979. PMID: 517883

5

Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer.

Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL, Hersh EM, Freireich EJ, Gehan EA. Buzdar AU, et al. Among authors: hortobagyi gn. Cancer. 1978 Mar;41(3):1064-75. doi: 10.1002/1097-0142(197803)41:3<1064::aid-cncr2820410340>3.0.co;2-q. Cancer. 1978. PMID: 638948

6

Overview of new treatments for breast cancer.

Hortobagyi GN. Hortobagyi GN. Breast Cancer Res Treat. 1992;21(1):3-13. doi: 10.1007/BF01811959. Breast Cancer Res Treat. 1992. PMID: 1356516

7

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Walters RS, et al. Among authors: hortobagyi gn. Invest New Drugs. 1992 Apr;10(1):43-4. doi: 10.1007/BF01275480. Invest New Drugs. 1992. PMID: 1376723 Clinical Trial.

8

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

9

Bone metastasis in breast cancer.

Theriault RL, Hortobagyi GN. Theriault RL, et al. Among authors: hortobagyi gn. Anticancer Drugs. 1992 Oct;3(5):455-62. doi: 10.1097/00001813-199210000-00002. Anticancer Drugs. 1992. PMID: 1450438 Review.

10

Activity of ifosfamide in breast cancer.

Hortobagyi GN. Hortobagyi GN. Semin Oncol. 1992 Dec;19(6 Suppl 12):36-41. Semin Oncol. 1992. PMID: 1485173 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,106 results

Search Page

Filters